- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06411756
Physical Activity Centers Empowerment (PACE)
Physical Activity Intervention Co-created and Tested With African American Colorectal Cancer Survivors
This research study tests the feasibility of the Physical Activity Centers Empowerment (PACE) physical activity intervention for African American individuals diagnosed with colorectal cancer.
Feasibility will be measured as intervention reach, effectiveness, adoption, implementation, and maintenance. Seventy-two subjects will be recruited to conduct a pilot two-group, randomized repeated measures study.
Study Overview
Status
Conditions
Detailed Description
The purpose of this research is to improve the quality of life for underserved cancer survivors by increasing physical activity. A physical activity intervention will be tested for feasibility with African American cancer survivors. The project will serve as a foundation for intervening with other underserved cancer survivors.
Feasibility will be measured as intervention Reach, Effectiveness, Adoption, Implementation, and Maintenance, following the RE-AIM framework. Survey and biomarker data will be collected at baseline, 3 and 9 months later. These time points will facilitate exploration of changes pre- and post-intervention, and to determine if effects are maintained 6 months after completing the intervention. Our primary hypothesis is that the intervention will be feasible to deliver.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina at Chapel Hill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- self-identifying as AA of Black,
- diagnosis of CRC,
- scheduled to receive chemotherapy,
- age 18 years or older,
- no contraindications to unsupervised PA as determined by the PA readiness questionnaire,
- oncologist approval to participate, and
- a smartphone for Fitbit syncing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Intervention Arm
Subjects will receive access to the video library, a Fitbit, a daily adaptive step goal that will be sent via text message with a short positive message; and monthly Zoom meetings, led by the research team, to discuss physical activity with other study subjects.
|
Culturally targeted narrative videos will be sent via email.
A Fitbit activity tracker is a wireless wearable device that monitors physical fitness activity.
A daily adaptive step goal that will be sent via text message with a short positive message.
Monthly Zoom meetings, led by the research team, to discuss physical activity with other study subjects.
Access to Physical Activity Centers Empowerment (PACE) website.
|
|
Other: Control Arm
Subjects will receive access to the video library after the study period (after the 9-month assessment).
|
A Fitbit activity tracker is a wireless wearable device that monitors physical fitness activity.
Printed materials from the American College of Sport's Medicine's "Moving through Cancer" campaign.
Printed materials from the American College of Sports Medicine's "Moving through Cancer" campaign.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility Reach- Recruitment
Time Frame: 18 months
|
Feasibility Reach- Recruitment is measured by the number of participants screened, ineligible, eligible, enrolled and declined participation.
|
18 months
|
|
Feasibility Retention
Time Frame: 18 months
|
Retention is measured by the frequency of enrolled participants continued study interventions
|
18 months
|
|
Average weekly steps
Time Frame: 3 months
|
Average weekly steps and the frequency of participants achieving daily step goals.
Daily steps are collected via Fitbit Inspire activity tracker.
Differences in daily steps and the frequency of meeting daily step goals between the intervention and control arms.
|
3 months
|
|
Weekly participation in mild, moderate, and vigorous exercise
Time Frame: 3 months
|
Weekly participation in mild, moderate, and vigorous exercise is time spent on physical activity each week is measured subjectively using the Godin Leisure-time Exercise Questionnaire (GLTEQ) and objectively by the Fitbit Inspire activity tracker.
The GLTEQ asks participants to self-report how many times they do strenuous, moderate, and mild or light exercise each week and the average duration of exercise.
The intervention effectiveness is operationalized by the differences in minutes of doing mild, moderate, and vigorous physical activity between the intervention and control arms.
|
3 months
|
|
Daily engagement in sedentary behaviors
Time Frame: 3 months
|
Daily engagement in sedentary behaviors will be measured as time spent on sedentary behaviors per day is measured subjectively by a 10-option Likert scale called the Sedentary Behavior Questionnaire.
Participants are asked to select one of the following options: none,<=15 minutes, 30 minutes,1 hour,2 hours,3 hours, 4 hours, 5 hours, and 6 hours or more" to estimate the time they spend doing each sedentary behavior on a typical week and a typical weekend day.
The behaviors include watching television, playing computer or video games, sitting and listening to music on the radio, tapes, or CDs, sitting and talking on the phone, doing paperwork or computer work, sitting and reading a book or magazine, playing a musical instrument, doing artwork or crafts, and sitting and driving a car, bus or train.
The total daily sedentary score ranges from 0 to 81.
Daily sedentary time is also recorded objectively by the Fitbit Inspire activity tracker.
|
3 months
|
|
Adaption of the study
Time Frame: Up to 18 months
|
Adaption of the study will be measured by the percentage of contacted individuals who meet study criteria to participate in the study.
|
Up to 18 months
|
|
Implementation of the video library
Time Frame: Up to 3 months
|
Implementation of the video library: The percentage of participants who watched study-related video content.
|
Up to 3 months
|
|
Implementation of using FITBIT
Time Frame: Up to 3 months
|
Implementation of using FITBIT: The percentage of days that participants wear the study-issued Fitbits.
|
Up to 3 months
|
|
The differences between intervention and control arms
Time Frame: 3 months to 9 months
|
The Maintenance will be measured as the differences in intervention effects between intervention and control arms groups 6 months post-intervention (9 months post-baseline).
|
3 months to 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inflammation biomarkers level
Time Frame: Baseline, 3 months, 9 months
|
Inflammation biomarkers, including IL-4, IL-10, IL-6, and TNF-α, will be measured by collecting participants' blood samples using the Dried Blood Spot card.
The differences in inflammation biomarker levels between the intervention and control groups will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Comorbidities
Time Frame: Baseline, 3 months, 9 months
|
Comorbidities will be measured using the Self-administered Comorbidity Questionnaire.
Participants are asked to self-report whether they have or received treatment for 14 common health problems.
The comorbidity score ranges from 0 to 28.
Differences in comorbidity scores between the intervention and control arms will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Outcome expectations
Time Frame: Baseline, 3 months, 9 months
|
Outcome expectations will be measured using the modified Multidimensional Outcome Expectations for Exercise Scale, which has an internal consistency of 0.82, 0.84, and 0.81 for physical, self-evaluative, and social outcomes. Differences in outcome expectation scores between the intervention and control arms will be analyzed. This 5-point Likert scale contains 19 items with the outcome expectation score ranging from 19 to 95. A higher score indicates a higher expectation of doing physical activity for diverse health, cancer, social, and psychological outcomes. |
Baseline, 3 months, 9 months
|
|
Feasibility activity knowledge
Time Frame: Baseline, 3 months, 9 months
|
Physical activity knowledge will be measured using a 5-point behavioral capacity Likert scale that assesses participants' knowledge about types, intensity, frequency, and skills of doing physical activity.
The knowledge score ranges from 5 to 25.
A higher score indicates a higher level of knowledge about doing appropriate physical activity.
Differences in knowledge scores between the intervention and control arms will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Self-efficacy
Time Frame: Baseline, 3 months, 9 months
|
Self-efficacy will be measured using a nine-item barrier self-efficacy scale and a four-item task self-efficacy scale to assess participants' confidence in overcoming barriers to physical activity and ability to do physical activity.
The two self-efficacy scales have Cronbach's alpha of 0.96 and 0.89 among cancer patients, respectively.
The total self-efficacy score ranges from The total self-efficacy score ranges from 13 to 65.
A higher score indicates a higher level of confidence in overcoming barriers and doing physical activity.
Differences in total self-efficacy scores between the intervention and control arms will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Physical activity engagement
Time Frame: Baseline, 3 months, 9 months
|
Physical activity engagement is measured by a 6-point Likert scale that measures the habit strength for moderate-to-vigorous physical activity.
The total habit score ranges from 17 to 102.
A higher score indicates a greater engagement in physical activity.
Differences in habit scores between the intervention and control arms will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Physical activity enjoyment
Time Frame: Baseline, 3 months, 9 months
|
Enjoyment is measured by a short version of the Physical Activity Enjoyment Scale (4-item).
The enjoyment score ranges from 4 to 20.
A higher score indicates a higher level of enjoyment participants perceive from doing physical activity.
Differences in enjoyment scores between the intervention and control arms will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Pain score
Time Frame: Baseline, 3 months, 9 months
|
Pain will be measured using a 4-item 5-point Likert pain interference scale from the Patient-Reported Outcomes Measurement Information System (PROMIS) measures.
The pain score ranges from 4 to 20.
A higher score indicates a higher level of pain interfering with participants' activities.
Differences in the pain score between intervention and control groups will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Fatigue score
Time Frame: Baseline, 3 months, 9 months
|
Fatigue will be measured using a 4-item 5-point Likert fatigue scale from the PROMIS measures.
The fatigue score ranges from 4 to 20.
A higher score indicates a higher level of fatigue.
Differences in the fatigue score between intervention and control groups will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Depression score
Time Frame: Baseline, 3 months, 9 months
|
Depression will be measured using a 4-item 5-point Likert emotional distress scale from PROMIS measures.
The depression score ranges from 4 to 20.
A higher score indicates a higher level of depression.
Differences in the depression score between intervention and control groups will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Bowel dysfunction score
Time Frame: Baseline, 3 months, 9 months
|
Bowel dysfunction will be measured using a 5-point Likert scale from the PROMIS that measures gastrointestinal diarrhea and constipation.
The bowel dysfunction score ranges from 15 to 75.
A higher score indicates a higher gastrointestinal discomfort participants have.
Differences in the score between intervention and control groups will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Sleep quality
Time Frame: Baseline, 3 months, 9 months
|
Sleep quality will be measured using a 4-item 5-point Likert scale from the PROMIS measures.
The sleep score ranges from 4 to 20.
A higher score indicates a better sleep quality.
Differences in the sleep score between intervention and control groups will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Neurotoxicity
Time Frame: Baseline, 3 months, 9 months
|
Neurotoxicity will be measured using a 4-item 5-point Likert scale from the PROMIS measures.
The neurotoxicity score ranges from 4 to 20.
A higher score indicates greater neurotoxicity symptoms participants report.
Differences in the neurotoxicity score between intervention and control groups will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Quality of life score
Time Frame: Baseline, 3 months, 9 months
|
Quality of life score will be measured using the 36-item Short Form Health Survey.
The quality of life score ranges from 0 to 100.
The score for each item in the form ranges from 0 to 100 and the average scores of items representing general physical, mental, and social health are calculated, respectively.
A higher score indicates better general physical, mental, or social health.
Differences in the score between intervention and control groups will be analyzed.
|
Baseline, 3 months, 9 months
|
|
Dietary behaviors
Time Frame: Baseline, 3 months, 9 months
|
Dietary behaviors are measured by the Rapid Eating Assessment for Participants (Shortened Version, 16 items).
The diet score ranges from 1 to 46.
A higher score indicates that the participant follows healthier dietary behaviors.
Differences in diet scores between the intervention and control arms will be analyzed.
|
Baseline, 3 months, 9 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Rachel Hirschey, Ph.D, RN, UNC Lineberger Comprehensive Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCCC2143AIM2
- 1K23MD015719-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Neoplasms
-
NuCana plcCompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States, France, United Kingdom
-
University of ChicagoVerastem, Inc.SuspendedColorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...CompletedColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
The Queen Elizabeth HospitalNovartis; AmgenCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalAustralia
-
Novartis PharmaceuticalsCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
ProgenaBiomeWithdrawnColorectal Neoplasms | Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Carcinoma | Colorectal Adenocarcinoma | Colorectal SarcomaUnited States
-
Bristol-Myers SquibbNovartisCompletedColorectal Cancer | Colorectal Neoplasm | Colorectal Tumors | Colorectal CarcinomaUnited States, Canada, Spain, Argentina, Australia, Belgium, Czechia, Italy, Chile, Germany
-
National Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal AdenocarcinomaUnited States
-
Endeavor HealthEnrolling by invitationColorectal Cancer | Colorectal Adenoma | Colorectal PolypUnited States
Clinical Trials on Narrative videos
-
University of Massachusetts, BostonCompleted
-
Uniformed Services University of the Health SciencesThe Miriam HospitalCompletedOptimizing a Multi-Modal Intervention to Reduce Health-Risking Sexual Behaviors: Component SelectionSexually Transmitted Infections | Pregnancy, Unplanned | Military PersonnelUnited States
-
Retina Foundation of the SouthwestRecruiting
-
Riphah International UniversityRecruiting
-
Sarah SchlegelHarvard Catalyst Pilot GrantRecruitingHypospadias | DSDUnited States
-
German Cancer Research CenterUniversity of Music, Drama, and Media HannoverCompleted
-
University of WashingtonNational Institute of Mental Health (NIMH)Not yet recruitingHiv | Substance Use | Mental Health Issue
-
Catalan Institute of HealthRecruitingOveruse SyndromeSpain
-
German Cancer Research CenterUniversity of Music, Drama, and Media HannoverCompleted
-
Mustafa Kemal UniversityNot yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes Self-management | Diabetes EducationTurkey (Türkiye)